Abbott K L, Harman G S
Wilford Hall Medical Center/PSMH, Lackland AFB, TX 78236-5300, USA.
Anticancer Drugs. 1995 Aug;6(4):489-97. doi: 10.1097/00001813-199508000-00001.
Malignant melanoma, once disseminated, is associated with very short survival times and has proven highly resistant to systemic therapy. Although many chemotherapeutic agents can produce small response rates in these patients, the most consistent responses occur with dacarbazine (DTIC). Numerous combination regimens, with and without DTIC, have been tested against disseminated melanoma, with varying and inconsistent outcomes. The most encouraging results have occurred with the combination of DTIC, cisplatin, BCNU and tamoxifen. The use of high-dose chemotherapy with and without autologous bone marrow support and the addition of biologic agents such as inteferon-alpha and interleukin-2 to conventional chemotherapy have also been actively investigated. This paper reviews the various approaches taken against disseminated melanoma employing systemic chemotherapy.
恶性黑色素瘤一旦发生播散，其生存期极短，且已证实对全身治疗具有高度抗性。尽管许多化疗药物可使这些患者产生较低的缓解率，但达卡巴嗪（DTIC）的疗效最为稳定。针对播散性黑色素瘤，人们已经测试了多种含或不含DTIC的联合治疗方案，结果各异且不一致。DTIC、顺铂、卡莫司汀（BCNU）和他莫昔芬联合使用取得了最令人鼓舞的结果。同时，人们也在积极研究使用含或不含自体骨髓支持的大剂量化疗，以及在传统化疗中添加生物制剂如α-干扰素和白细胞介素-2的效果。本文综述了采用全身化疗治疗播散性黑色素瘤的各种方法。
